Latest news with #Emeryville
Yahoo
10 hours ago
- Yahoo
Escaping gas-station burglars spray smoke at Emeryville cop car
The Brief Burglars ram stolen car into gas station food mart in Emeryville As police arrive, burglar in escaping car unleashes smoke at cop car Intruders stole cigarettes but couldn't get into ATM Emeryville - It's a first in the Bay Area – a group of burglars unleashing smoke at a Emeryville police car after a gas-station smash and grab. A passenger in the back apparently sprayed smoke, evidently trying to obscure the officer's view. "Arriving on scene and not knowing what you're driving into is very scary," said Emeryville police Officer Baylee Worthen, a department spokeswoman. It happened at about 4:15 a.m. Monday morning at the 76 gas station at Powell Street and Christie Avenue. Worthen said the smoke temporarily blinded the officer. "It was some kind of smoke device, so it fogged the air, so the officer was not able to clearly see what was going on when they were arriving on scene," Worthen said. What they're saying The officer drove after the suspects. But because Emeryville police, like many other agencies, has a strict pursuit policy, the officer was unable to chase and catch the suspects. It all began when intruders arrived in a caravan and repeatedly backed a stolen Honda Civic into the gas station's food mart. Burglars ran inside through the hole. "There was an employee on site, but it sounds like they locked themselves in the bathroom during this incident," Worthen said. What we know The Civic that rammed the store was abandoned at the gas station. Also abandoned was an ATM that the intruders couldn't get into. But the store owner told KTVU they did escape with several cartons of cigarettes. Investigators are combing through surveillance video for clues. Later Monday, in what has become a familiar sight, crews kept busy boarding up the store an making repairs. The damage and frustration, extensive. Emeryville police said FLock Safety cameras spotted the two other cars going into Oakland. No arrests have been made and the investigation is continuing. Henry Lee is a KTVU crime reporter. E-mail Henry at and follow him on Twitter @henrykleeKTVU and The Source KTVU reporting, Emeryville police
Associated Press
a day ago
- Business
- Associated Press
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote 'FOR' All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., June 9, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ('Dynavax' or the 'Company'), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote 'FOR' all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – at the Company's upcoming Annual Meeting of Stockholders on June 11, 2025 (the '2025 Annual Meeting'). Since 2019, Dynavax has successfully executed a strategic repositioning of our business, and our refreshed Board is executing a plan that is delivering significant stockholder value. In direct contrast, Deep Track – which has no experience developing and executing corporate strategy, operations, or finance – is insistent on implementing its strip-mining plan for Dynavax, jeopardizing a strong platform with significant long-term growth opportunities for a near-term payoff of a considerably lower value. Simply put: there is no case for change, and changing course to Deep Track's purported plan will destroy long-term value and is not in the best interests of all stockholders. Re-electing all four of our nominees is essential to our ability to continue driving value for all stockholders. Without Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun, the Board would be deprived of essential strategic leadership, vaccine expertise, senior public biotechnology and M&A experience, as well as deep industry financial expertise – qualifications that none of Deep Track's candidates can adequately match. Deep Track's principal, Brett Erkman, is beholden to his own hedge fund investors – not our stockholders – and has demonstrated an inability to be open-minded. Donald Santel lacks vaccine industry experience and his public company executive experience ended ten years ago. In short, Deep Track's nominees are far less qualified than all of our current directors. Make no mistake – Deep Track is attempting to gain control of Dynavax to implement its flawed plan, which would be detrimental to the long-term value we are generating for our stockholders. Independent proxy advisory firms Institutional Shareholder Services ('ISS') and Egan-Jones agree and recommend that stockholders support all of Dynavax's director nominees. ISS noted that Deep Track has failed to present a compelling case for change and called attention to Deep Track's cherry picked and highly misleading materials throughout its campaign – 'There are serious concerns with the dissident's presentation of TSR…The dissident's attempt to suggest otherwise through a blatantly distorted TSR analysis has only diminished its credibility."1 Glass, Lewis & Co. ('Glass Lewis') acknowledged the significant stockholder returns we have been generating, our differentiated capital allocation plan, and the meaningful refreshment and high caliber Board we have in place. Perhaps most importantly, Glass Lewis put a fine point on the legitimate concerns stockholders should have in electing Mr. Erkman to the Board – noting that 'his fiduciary experience in a boardroom setting remains untested' and 'may raise legitimate questions about Mr. Erkman's ability to balance Deep Track's position with the broader interests of all shareholders."2 Here's why we encourage you to vote for ALL four of Dynavax's nominees: With our 2025 Annual Meeting fast approaching on June 11, it is extremely important that you vote as soon as possible, no matter how many shares you own. We urge you to vote 'FOR' all four of Dynavax's director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – on the GOLD proxy card today. Dynavax stockholders who need assistance in voting their shares may call the Company's proxy solicitor, MacKenzie Partners, at 1-800-322-2885. Advisors Goldman Sachs & Co. LLC is serving as financial advisor to Dynavax and Cooley LLP is serving as legal counsel. About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit Forward-Looking Statements This communication contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as 'continue,' 'expect,' 'will,' 'plan,' 'would,' and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding expected contributions from our current directors, expectations regarding delivering value for our stockholders, market share and size of the market, our business strategy and long-term performance. Actual results may differ materially from those set forth in this communication due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change, risks relating to our ability to commercialize and supply HEPLISAV-B, the risks that market size or actual demand for our products may differ from our expectations, risks related to the timing of completion and results of current clinical studies, risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, and risks related to the implementation of our long-term growth objectives, as well as other risks detailed in the 'Risk Factors' section of our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 and any periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at is not incorporated by reference in our current periodic reports with the SEC. Important Additional Information and Where to Find It On April 17, 2025, the Company filed a definitive proxy statement on Schedule 14A (the 'Proxy Statement') and form of accompanying GOLD proxy card with the U.S. Securities and Exchange Commission (the 'SEC') in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company's director nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other document that the Company has filed or may file with the SEC in connection with any solicitation by the Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING GOLD PROXY CARD AND OTHER RELEVANT DOCUMENTS FILED WITH, OR FURNISHED TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the Proxy Statement, accompanying GOLD proxy card, any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company with the SEC at no charge at the SEC's website at Copies will also be available at no charge at the Company's website at Certain Information Regarding Participants This communication is neither a solicitation of a proxy or consent nor a substitute for any proxy statement or other filings that may be made with the SEC. The Company, its directors, its director nominees and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the 2025 Annual Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities holdings or otherwise, is available in the Proxy Statement, which was filed with the SEC on April 17, 2025, including in the sections captioned 'Compensation Discussion and Analysis,' 'Summary Compensation Table,' 'Grants of Plan Based Awards,' 'Outstanding Equity Awards at Fiscal Year End,' 'Pay Ratio Disclosure,' 'Director Compensation,' 'Certain Transactions,' 'Security Ownership of Certain Beneficial Owners and Management,' and 'Supplemental Information Regarding Participants in the Solicitation.' To the extent that the Company's directors and executive officers have acquired or disposed of securities holdings since the applicable 'as of' date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in Ownership of Securities on Form 4 or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with the SEC. These documents are or will be available free of charge at the SEC's website at For Investors: Paul Cox [email protected] 510-665-0499 Or MacKenzie Partners, Inc. Bob Marese / John Bryan Toll-Free: 1-800-322-2885 [email protected] For Media: Dan Moore / Tali Epstein [email protected] 1 Source: ISS report dated May 23, 2025. Permission to use quotes neither sought nor obtained. 2 Source: Glass Lewis report dated June 3, 2025. Permission to use quotes neither sought nor obtained. 3 As of April 17, 2025, the date Dynavax filed its definitive proxy. View original content to download multimedia: SOURCE Dynavax Technologies
CBS News
4 days ago
- General
- CBS News
Architect Eugene Tssui draws inspiration from nature to revolutionize sustainable design
For architect and environmental activist Eugene Tssui, the future of sustainable design starts with a return to nature and a radical shift in mindset. "The environment is our home, and our home is dying," Tssui said. "We need to address that in a way where all of us need to change the way we think, and live, and behave." Known for his unconventional, biomimicry-inspired designs, Tssui has completed multiple residential projects across the Bay Area, each emphasizing ecological harmony and renewable energy. One of his latest efforts, The Sky Park Arch, will be Emeryville's first zero-energy building — a milestone in his ongoing mission to fuse architecture with nature's principles. "Architecture accounts for at least 45 percent of the world's toxic pollution," Tssui said. "And it's a shame that architects aren't a voice for letting that be known." Tssui, recently named Emeryville's 2025 Architect/Artist in Residence, sees architecture not just as a profession but as a platform for change. His design philosophy draws heavily from the natural world, where he believes the answers to many environmental challenges already exist. "The electric eel can create 600 volts of energy instantaneously just through its musculature, just through the electro nerve system inside of its body," he said. "I'm thinking now, if we knew how to biologically create electricity, it would revolutionize the world. We could have electricity that doesn't pollute at all." He argues that modern architecture still relies too heavily on outdated, industrial-age methods, failing to consider the innovations inherent in biology. "All of these miracles and secrets actually occur in nature that we are not even investigating," Tssui said. "And they could just revolutionize the way we think about energy." Tssui's work continues to challenge the conventional boundaries of design, pushing toward a vision of architecture that not only serves humanity but heals the planet. Because for Tssui, conserving energy isn't just a goal. It's the fuel behind his life's work.
Reuters
6 days ago
- Business
- Reuters
Glass Lewis backs two of Deep Track's four nominees in Dynavax fight
NEW YORK, June 4 (Reuters) - Proxy advisory firm Glass Lewis urged Dynavax Technologies (DVAX.O), opens new tab shareholders to elect two of investment firm Deep Track Capital's four director nominees, arguing change is needed because the company has not been responsive enough to shareholders. Glass Lewis recommended in a report that shareholders vote for Brett Erkman, a Deep Track managing director, and biotech industry executive Donald Santel to replace sitting directors Brent MacGregor and Scott Myers, the current board chair. Emeryville, California-based Dynavax, which makes a vaccine designed to prevent the hepatitis B infection that can lead to chronic liver disease and death, has an 11-member board but only four are standing for election this year. Shareholders will cast ballots at the June 11 annual meeting unless the two sides reach a settlement beforehand. Proxy advisory firm recommendations often guide how money managers vote on hot button issues like corporate elections and mergers. "Shareholders should support the change of two incumbent board seats given the company's prolonged capital conservatism and the board's limited responsiveness to shareholder feedback," the report said. The two Deep Track nominees would bring "relevant and differentiated experience to the board," it added. Erkman has worked as a private equity investor in life sciences and Santel is a life sciences executive who has done deals. Deep Track, Dynavax's second largest shareholder with a nearly 15% stake, wants new directors to prioritize development of the company's hepatitis B vaccine Heplisav instead of pursuing new acquisitions. Dynavax is valued at $1.2 billion and its share price has dropped 22% this year. In May, Institutional Shareholder Services, Glass Lewis' bigger rival, recommended that all company directors be reelected, arguing Deep Track failed to make its case for change. A Deep Track representative welcomed the report. Dynavax disagreed with the recommendation, saying Glass Lewis noted its board "has been meaningfully refreshed with high quality and sector-specific expertise," a company representative said.
Globe and Mail
27-05-2025
- Business
- Globe and Mail
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. • Goldman Sachs 46th Annual Global Healthcare Conference (Miami, June 9–11, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, June 9, 2025 at 3:20–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcasts will be available in the investor section of the company's website at and will be archived for 30 days following the presentations. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
